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Abstract
Background: Type 2 diabetes mellitus (T2DM) has become a world-wide epidemic. This chronic metabolic
disease has a major impact on life expectancy and on quality of life. The burden of this disease includes a
number of co-morbidities. However, estimates of prevalence, incidence and associated diseases as well as
the current temporal development and regional differences are largely missing for South Western Germany.
Methods: Lifetime diagnosis-based prevalence, incidence and presence of concomitant co-morbidities were
examined between the years 2007 and 2010 in the claims data set of all insured persons of the AOK Baden-
Wuerttemberg, a large statutory health insurance. The analysis was based on the respective WHO-ICD-10
codes. Data were standardized for age and sex on the residential population of about 10 million inhabitants
of South Western Germany.
Results: The total study cohort involved approximately 3.5 million persons each year. The standardized
diagnosis-based prevalence (SDP) of T2DM rose from 6.6 %, 7.4 %, 8.0 %, up to 8.6 % in the years 2007 to
2010. Yearly SDP was between 14.0 % and 18.9 % at an age range of 60 to 64 years and between 26.7 %
and 31.8 % at an age of 75 years or older. In the year 2010 the regional distributions of standardized
diagnosis-based prevalence were between 7.6 % and 11.6 %, respectively. Incidence rates were 8.3 in 2008,
7.8 in 2009, and 8.7 in 2010 (all rates per 1000). The excess disease risk (odds ratio) of T2DM was for
adiposity 2.8 to 3.0, hypertension 2.4 to 3.7, coronary heart disease 1.8 to 1.9, stroke 1.7 to 1.8, renal
insufficiency 2.8 to 3.4, and retinopathy 2.8 to 2.9 in the years 2007 to 2010. These co-morbidities appeared
several years earlier compared to the non-diabetic population.
Conclusions: T2DM is common and increasing in South Western Germany. In particular a quarter of the
population in higher ages was afflicted by T2DM. Interestingly a region-specific pattern was observed as well
as an increase in numbers during earlier years in life. Our data underline the need for diabetes awareness
programmes including early diagnosis measures as well as structured and timely health surveys for major
diseases such as T2DM and its concomitant co-morbidities.
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Background
Type 2 diabetes mellitus (T2DM) is one of the most fre-
quent chronic metabolic diseases. According to the recent
German Health Interview and Examination Survey for
Adults (DEGS1 survey) in Germany 7.2 % suffer from all
types of diabetes [1]. Chronic hyperglycaemia can damage
many organ systems and represents a considerable health
challenge and economic burden for the individual as well
as for the society [2–5]. The prevalence, lifetime risk, and
concomitant co-morbidities determine the burden of the
disease [3, 6–8]. In particular micro- and macro-vascular
complications including coronary heart diseases, myocar-
dial infarction, stroke, retino-, neuro-, or nephropathy and
arterial occlusive disease are important [6, 8–11]. These
complications have a direct negative impact on the patient
but also to the society in general by significantly increasing
the healthcare costs [12–17]. Beside functional limitations
in daily life, T2DM can lead to a shortening of the life
expectancy by several years [8, 18, 19].
There is evidence that the prevalence of T2DM has
risen considerably over the last decades [1, 14]. In
addition, the data of the DEGS1 survey show regional
differences in Germany with a trend of lower preva-
lences in the southern parts [1]. A similar gradient of
known T2DM was found in an analysis based on the
results from up to six population-based studies in
Germany [20, 21]. As of today only the analysis of
claims data of one other statutory health insurance has
determined a single T2DM’s diagnosis-based prevalence
of 4.85 % for South Western Germany [22]. However,
no further analyses of the T2DM’s prevalence and their
time-related development have been reported for South
Western Germany, which is comprised of a relatively
prosperous society with an average income in the upper
third of Germany [23]. Furthermore, no study has
addressed regional differences of T2DM’s prevalences
within this region.
The aim of this retrospective cohort study in the state
Baden-Wuerttemberg with a population of over 10 mil-
lion was to investigate incidence, prevalence, and tem-
poral trends over several years as well as regional
patterns of T2DM within claims data of the members of
the AOK Baden-Wuerttemberg, a large health insurance
in South Western Germany. The respective data were
evaluated after adjustment for age and sex and standard-
ized on the residential population of South Western
Germany. Moreover, in a supplementary analysis the




The routine claims data of the AOK Baden-Wuerttemberg,
a large statutory health insurance, was used for this
DiMBaWue-study (diabetes mellitus in Baden-Wuerttemberg
study). The AOK Baden-Wuerttemberg includes about 4
million insurants in South Western Germany. The respective
state Baden-Wuerttemberg of the federal republic of
Germany has over 10 million inhabitants.
Ascertainment of prevalent diabetes mellitus
All insured persons of the AOK Baden-Württemberg
permanently enrolled for at least one calendar year
between 2007 until 2010 were included in this study.
The cohort population included about 3.5 million per-
sons per year (Table 1). To identify people with diabetes
the recorded claims diagnoses and the prescriptions of
medications were used according to the slightly modified
algorithm of the investigations of claims data of the
AOK Hessen [24, 25]. We identified persons with claims
related to T2DM considering the diagnoses E11-E14
according to the 10th revision of the International
Classification of Diseases only (ICD-10). However,
diagnosis coded with E13 were excluded from the
analysis due to the frequently use of this code for
coding of pancreoprive diabetes, which pathophysio-
logically has similarities to type 1 but not to T2DM.
A diabetes-related claim had to be coded at least in 3
of 4 quarters of a year. Alternatively, repeated pre-
scriptions of anti-diabetic drugs (ATC code A10A or
A10B) in more than one quarter of a year had to be
documented to qualify as T2DM case. The recording
Table 1 Basic information of the used claims data
2007 2008 2009 2010
Total number of insured persons 4 048 709 3 931 988 3 906 411 3 954 172
Age in years (mean) 43.0 43.5 43.7 43.7
Sex (men & women) 47.1 % & 52.9 % 47.0 % & 53.0 % 47.1 % & 52.9 % 47.2 % & 52.8 %
Number of persons insured permanently
over the respective year (study population)
3 538 793 3 483 739 3 459 461 3 492 326
Proportion of the included study population
compared to total number of insured persons (%)
87.4 % 88.6 % 88.6 % 88.3 %
Age in years (mean) 44.4 44.8 40.0 45.0
Sex (men & women) 46.2 % & 53.8 % 46.3 % & 53.7 % 46.4 % & 53.6 % 46.4 % & 53.6 %
Boehme et al. BMC Public Health  (2015) 15:855 Page 2 of 18
of one prescription of an anti-diabetic drug in combin-
ation with a diabetes-related claim (includes measurement
of glucose or HbA1c) was also valuated as indicative for
T2DM. To analyze the prevalence of diabetes in different
districts of South Western Germany the postal ZIP-code
of the insured person was used. The data of each calendar
year were separately analyzed using the described algo-
rithm each time.
Ascertainment of incident diabetes mellitus
For identification of incident type 2 diabetes the same
procedure was applied. However, only persons continu-
ously enrolled in the health insurance plan for two
consecutive calendar years were considered. For each
identified person with a diabetes-related claim in the
second year the previous year was checked for the pres-
ence of any diabetes-related claim. If no prior diabetes-
related claim was detected, the patient was considered
as incident case in the second of the two years.
Ascertainment of concomitant co-morbidities
To identify relevant concomitant co-morbidities and to
determine the burden of disease data sets of persons
with and without T2DM were checked for the following
ICD-10 codes: adiposity (E66), hypertension (I10-I13),
coronary heart diseases (I20-I22, I24-I25), chronic renal
insufficiency (N18, N08.3), stroke and cerebral circulatory
disorders (I63-I64), and retinopathy (H35, H36.03). In
addition, for estimating the excess risk of disease in a
case–control study, each insured person with type 2 dia-
betes was age- and sex-matched to one control of the
same calendar year. Controls were randomly chosen
among the subjects without diabetes (no documented
diagnosis E10-E14) and had to be permanently insured
during this calendar year. All insured persons with T2DM
were included in this case–control study.
Statistical methods
The statistical analysis was performed in a two-step
approach. The primary data analysis and the compil-
ation of the cohort were carried out through the
AOK Baden-Wuerttemberg (Department of Business
Intelligence) by internal analysis of their claims data.
The AOK Baden-Württemberg provided for further
analysis an anonymized dataset with disease rates aggre-
gated on age groups and sex for the period 2007 until
2010. The age groups comprised 5 year-categories except
the first age group covering the ages 0 until 20 years.
Prevalence and incidence rates were standardized on
the total population of South Western Germany consid-
ering the resident population at 31st of December of the
respective year (data source: Statistical Federal Office,
Wiesbaden 2013, GENESIS-Online, feature code
12411–0012 - last accessed 10.03.2013 [26]). Only the
determination of the excess risk of selected co-morbidities
was performed with the original data set from the case–
control cohort using no further standardization. The
population of the 44 distinct districts of South Western
Germany was standardized on the averaged resident
population of the year (data source: Statistical Offices of
the Federation and the Countries, 2013, Regionalstatistik
GENESIS-Online feature code 173-32-4 - last accessed
20.02.2013 [27]).
To calculate confidence intervals for the rates, the vari-
ance estimation considered the direct standardization
[28]. Differences in time trends between 2007 and 2010
were quantified with the Cochran-Armitage-trend test. To
compare persons with and without diabetes standardized
prevalence ratios (SPR) or - in the case–control study -
odds ratios were calculated and complemented with 95 %
confidence intervals (CI). These calculations and prepara-
tions of all figures were performed with SAS Version 9.3
(SAS Institute Inc., Cary, NC, USA).
To assess the shift of the co-morbidity distributions
for persons with T2DM the semi-maximum values of
the concomitant co-morbidities were calculated. The age
groups were transformed into a continuous age in years
using the class means. The prevalence curves of each
concomitant co-morbidity were modelled stratified for
diabetes with fractional polynomials (Software r Version
2.15.1 http://cran.r-project.org, Paket mfp) [29, 30]. For
each model the fit (R2) was assessed. The intersection of
the semi-maximum values and the prevalence curves
were determined with the Ridders method (Software r
Version 2.15.1 http://cran.r-project.org, Paket pracma)
[31]. The interpolated age at the respective intersections
was subsequently compared between persons with and
without type 2 diabetes by calculating the difference.
Results
Table 1 summarizes baseline information of the claims
data used. The number of total persons insured varied
between 3.9 and over 4.0 million for the years 2007 to
2010. Approximately 3.5 million were permanently in-
sured for the whole year. This reflects between 87.4 %
and 88.6 % of all insured persons and between 36.4 %
and 37.7 % of the total residual population of South
Western Germany. The mean ages in the four years var-
ied between 44.4 and 45.0 years and were comparable
among the respective years.
Prevalence and incidence of diabetes
Figure 1 shows a rise in the estimated standardized life-
time diagnosis-based prevalence of T2DM from 6.6 %
(men (m): 6.5 %, women (w) 6.8 %) in the year 2007 to
7.3 % (m: 7.3 %, w: 7.4 %) in 2008 and 8.0 % (m: 8.0 %,
w: 8.0 %) in 2009 up to 8.6 % (m: 8.6 %, w: 8.6 %) in the
year 2010 (overall differences among the years p < 0.001,
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for confidence intervals see Table 2). This statistically
significant increase was also evident provided that the
residential population of 2007 was used as the reference
for standardization.
Figure 2 gives the diagnosis-based prevalence (panel a)
and incidence (panel b) according to 5 years age groups.
An increase in the diagnosis-based prevalence was seen
in all age categories already starting at younger ages. It
exceeded 5 % in the age group of 50 to 54 years, was ap-
proximately 15 % in the age group of 60 to 64 years, and
over 25 % in the age groups older than 75 years. With
regard to the latter, the diagnosis-based prevalence
remained high whereas a decrease of the respective inci-
dences was seen. A statistically significant difference
among men and women was observed. Females reached
the prevalence levels in males with a time difference of
about 5 years of age (data not shown in detail).
In addition, the diagnosis-based prevalence of T2DM
was separately calculated for the population aged
20 years and over to avoid the influence of potential
misclassification of T2DM in children and adolescent.
The respective diagnosis-based prevalences were 8.3 %
(m: 8.3 %, w: 8.4 %), 9.2 % (m: 9.2 %, w: 9.2 %), 9.9 % (m:
10.1 %, w: 9.9 %), and 10.6 % (m: 10.8 %, w: 10.5 %) for
the years 2007 to 2010 respectively (further details see
Table 3). In addition, the standardized incidence rates
(all rates per 1000) of T2DM were 8.21 (m: 8.86, w 7.78)
for the year 2008, 7.69 (m: 8.32, w: 7.26) for the year
2009, and 8.62 (m: 9.17, w: 8.27) for the year 2010 (fur-
ther details see Table 4).
An additional analysis of the data of 2010 determined
the proportion of persons with T2DM on all persons
with any diabetes diagnosis in the records depending on
the specific ICD-10 codes used for analysis. This analysis
showed considering all persons with any ICD codes for
diabetes without further restrictions the following pro-
portions for each code: 12.1 % (E10), 82.2 % (E11), 0.2 %
(E12), 3.9 % (E13), and 53.0 % (E14) respectively, indicat-
ing multiple coding by the physicians. Using the respect-
ive ICD codes under the restriction that these were
männlich
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Fig. 1 Lifetime diagnosis-based prevalence of type 2 diabetes mellitus for the years 2007 to 2010. Only persons of the AOK Baden-Wuerttemberg
insured all four quarters of a year were analyzed and the results standardized for age and sex on the total residual population of South Western
Germany. (***p-value of trend test <0.001)
Table 2 Diagnosis-based prevalence and 95 % confidence intervals (CI)
Diagnosis-based prevalence of type 2 diabetes mellitus, standardized on the respective year
Year 2007 2008 2009 2010
Men Prevalence 6.5 % 7.3 % 8.0 % 8.6 %
95 % CI 6.49-6.54 7.26-7.30 7.97-8.01 8.61-8.66
Women Prevalence 6.8 % 7.4 % 8.0 % 8.6 %
95 % CI 6.75-6.79 7.40-7.45 8.00-8.05 8.55-8.60
Total Prevalence 6.6 % 7.3 % 8.0 % 8.6 %
95 % CI 6.61-6.64 7.31-7.34 7.95-7.99 8.55-8.58
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Fig. 2 Treatment prevalence (a) and incidence (b) of type 2 diabetes mellitus of 5 years age groups. The age group specific diagnosis-based
prevalence and incidence rates of insured persons of the AOK Baden-Wuerttemberg are shown for the years 2007 to 2010. Changes from 2007
to 2010 (prevalence) and 2008 to 2010 (incidence) were statistically significant different in all age groups (all p-values < 0.001)
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recorded alone and not together with other diabetes
specific codes, the proportions on all persons with a
diagnosis of T2DM were 40.9 % using E11, 0 % using
E12 or E13, and 13.5 % using E14 only. In addition, the
sole prescription of antidiabetic drugs or insulin without
a connection to a diabetes specific WHO-ICD-10 code
over the whole calendar year was evident in 0.1 % of all
insured persons only.
Importance of concomitant co-morbidities
As displayed in Fig. 3, the comparison of T2DM associ-
ated concomitant co-morbidities showed for all examined
diseases a much higher rate for persons with T2DM. For
the years 2007 to 2010 the standardized diagnosis-based
prevalence of persons with T2DM ranged from 30.8 %
(95 % CI: 30.7-30.9) to 33.3 % (95 % CI: 33.1-33.4) for
adiposity, from 72.6 % (95 % CI: 72.4-72.8) to 79.9 %
(95 % CI: 79.7-80.1) for hypertension, from 20.6 % (95 %
CI: 20.5-20.7) to 23.0 % (95 % CI: 22.9-23.1) for coronary
heart diseases, from 3.4 % (95 % CI: 3.4-3.5) to 4.2 %
(95 % CI: 4.1-4.2) for stroke, from 7.3 % (95 % CI: 7.2-7.4)
to 8.6 % (95 % CI: 8.5-8.7) for renal insufficiency, and from
24.6 % (95 % CI: 24.5-24.7) to 24.9 % (95 % CI: 24.8-25.0)
for retinopathy. It was considerable lower for subjects
without T2DM.
Table 5 shows the corresponding standardized preva-
lence ratios (SPR) of the burden of concomitant co-
morbidities in patients with T2DM compared to subjects
without for the year 2010 after standardization to the total
residual population of South Western Germany. For the
data for the years 2007 to 2010 see Additional file 1. The
SPR for adiposity ranged from 3.8 to 4.0, for hypertension
from 4.0 to 4.6, for coronary heart diseases from 5.8 to
6.4, for stroke from 6.5 to 8.1, for renal insufficiency from
6.2 to 11.8, and for retinopathy from 7.7 to 9.5 for the
respective year. However, the confidence intervals of the
point estimates are wide and reveal no differences among
these years for the different co-morbidities.
The further evaluation of the standardized semi-
maximum values of age group specific occurrence of
disease for the year 2010 revealed an age shift in case of
all examined concomitant co-morbidities (Table 6). For
this analysis the age groups of 20 years and older were
considered only to avoid the influence of potential mis-
classification of T2DM in children and adolescent. The
respective semi-maximum values were reached several
years earlier by persons with T2DM in comparison with
the persons without T2DM. The shift of the semi-
maximum to earlier ages was on average 11 to 12 years
for adiposity, 19 to 23 years for hypertension, 7 to 8 years
for coronary heart diseases, 4 to 5 years for stroke, 8 to
12 years for renal insufficiency, and 21 to 26 years for
retinopathy. For the data for the years 2007 to 2010 see
Additional file 2. The goodness of fit (R2) was > 0.90 for
most of the model adaptations indicating a very good
fitting of the estimated curves. Only slight differences
were seen among the years 2007 to 2010 when results
were stratified by sex. Figure 4 shows a graphical
Table 3 Diagnosis-based prevalence and 95 % confidence intervals (CI) for the age groups 20 years and older
Diagnosis-based prevalence of type 2 diabetes mellitus, standardized on the respective year, age group 20 years and older
Year 2007 2008 2009 2010
Men Prevalence 8.3 % 9.2 % 10.1 % 10.8 %
95 % CI 8.25-8.31 9.18-9-24 10.04-10.10 10.80-10.86
Women Prevalence 8.4 % 9.2 % 9.9 % 10.5 %
95 % CI 8.39-8.44 9.17-9.22 9.86-9.92 10.50-10.56
Total Prevalence 8.3 9.2 % 9.9 % 10.6 %
95 % CI 8.31-8.35 9.15-9.19 9.91-9.95 10.61-10.65
Table 4 Diagnosis-based incidence and 95 % confidence intervals (CI)
Diagnosis-based incidence of type 2 diabetes mellitus, standardized on the respective year (all rates per 1000)
Year 2008 2009 2010
Men Incidence (per 1000) 8.86 8.32 9.17
95 % CI 8.78-8.94 8.24-8.40 9.09-9.26
Women Incidence (per 1000) 7.78 7.26 8.27
95 % CI 7.71-7.85 7.19-7.34 8.19-8.35
Total Incidence (per 1000) 8.21 7.69 8.62
95 % CI 8.15-8.26 7.64-7.74 8.57-8.68
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comparison of the age shift of prevalence rates in per-
sons aged 20 years and older with and without T2DM
for the year 2010.
Finally the excess risk of disease was analyzed in the
nested case–control study estimating the prevalence
rates and the relative risk (odds ratio) for selected con-
comitant co-morbidities. The results for the year 2010
are shown in Table 7. For all included comorbidities a
significantly higher odds ratio was seen for T2DM. The
excess disease risk (odds ratios) for insured persons with
T2DM compared to subjects without diabetes varied for
adiposity from 2.8 to 3.0, for hypertension 2.4 to 3.7,
coronary heart diseases 1.8 to 1.9, stroke 1.7 to 1.8, renal
insufficiency 2.8 to 3.4, and retinopathy 2.8 to 2.9 for the
years 2007 to 2010. For the data for the years 2007 to
2010 see Additional file 3.
Regional patterns of diagnosis-based prevalence in the
distinct districts of South Western Germany
As displayed in Fig. 5 considerable differences were seen
in the lifetime diagnosis-based prevalence of T2DM in
the 44 distinct districts of South Western Germany in
the year 2010. After standardization on the residual
population of the districts, for determination of the
district-related burden of disease and e.g. direct regional
assessments of health care needs, the diagnosis-based
prevalences of T2DM ranged between 7.2 % (95 % CI:
7.1-7.3) and 11.5 % (95 % CI: 11.4-11.6) (m: 7.4 % (95 %
CI: 7.3-7.6) to 11.5 % (95 % CI: 11.3-11.6); w: 7.0 %
(95 % CI: 6.8-7.1) to 11.5 % (95 % CI: 11.3-11.7)). After
standardization of the data on the residential population
of South Western Germany (Fig. 5 b, d, and f), enabling
a direct comparison of the distinct districts irrespective
of age and sex distribution, diagnosis-based prevalences
were between 7.6 % (95 % CI: 7.5-7.6) and up to 11.6 %
(95 % CI: 11.58-11.62) (m: 7.9 % (95 % CI: 7.84-7.89) up
to 11.6 % (95 % CI: 11.56-11.62); w: 7.2 % (95 % CI:
7.23-7.27) up to 11.6 % (95 % CI: 11.59-11.64). Non
evident pattern between the prevalence and urban or
rural characteristics of the districts was found. The
diagnosis-based prevalence of several districts changed
to a higher as well as to a lower prevalence class after
standardization of the data on the residual population of
South Western Germany (Fig. 5).
Discussion
We provide estimates of prevalence, incidence and con-
comitant co-morbidities of T2DM in a population from
South Western Germany, which is comprised of over 10
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Fig. 3 Lifetime diagnosis-based prevalence of concomitant co-morbidities for the years 2007 to 2010. The rates of insured of the AOK Baden-
Wuerttemberg were stratified in persons without type 2 diabetes mellitus (T2DM) and with T2DM and standardized for age and sex on the total
residual population of South Western Germany of the respective year
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Table 5 Burden of selected concomitant co-morbidities 2010
Disease Men Women Total
(Year 2010) Standardized prevalence rates (95 % CI) SPR (95%CI) Standardized prevalence rates (95 % CI) SPR (95 % KI) Standardized prevalence rates (95 % CI) SPR (95 % CI)
Without T2DM With T2DM Without T2DM With T2DM Without T2DM With T2DM
Adiposity 5.99 (5.97-6.01) 27.11 (26.95-27.26) 4.53 (1.87-10.96) 9.83 (9.81-9.86) 34.49 (34.32-34.66) 3.51 (1.73-7.12) 8.08 (8.07-8.10) 31.13 (31.02-31.25) 3.85 (1.78-8.35)
Hypertension 17.84 (17.80-17.87) 74.68 (74.43-74.93) 4.19 (2.50-7.02) 20.84 (20.80-20.88) 79.12 (78.87-79.38) 3.8 (2.34-6.15) 19.37 (19.34-19.40) 77.01 (76.83-77.19) 3.98 (2.42-6.54)
Coronary heart disease 4.71 (4.69-4.73) 27.77 (27.61-27.92) 5.89 (2.22-15.65) 3.32 (3.31-3.34) 18.95 (18.83-19.08) 5.70 (1.78-18.29) 3.32 (3.31-3.34) 22.99 (22.89-23.08) 5.84 (2.01-17.02)
Stroke 0.70 (0.69-0.71) 4.73 (4.67-4.80) 6.77 (0.55-83.35) 0.60 (0.59-0.61) 3.66 (3.61-3.72) 6.10 (0.4-93.4) 0.64 (0.64-0.65) 4.15 (4.11-4.19) 6.47 (0.47-89.7)
Renal insufficiency 1.43 (1.42-1.44) 8.65 (8.56-8.73) 6.06 (1.03-35.66) 1.08 (1.07-1.09) 6.69 (6.62-6.76) 6.2 (0.81-47.33) 1.23 (1.22-1.24) 7.57 (7.52-7.63) 6.17 (0.92-41.5)
Retinopathy 2.61 (2.60-2.62) 23.71 (23.57-23.85) 9.08 (2.53-32.61) 3.82 (3.80-3.84) 25.86 (25.71-26.00) 6.77 (2.31-19.82) 3.24 (3.23-3.25) 24.83 (24.73-24.93) 7.66 (2.41-24.37)
The standardized prevalence ratios are shown for adiposity and several vascular determined concomitant diseases comparing insured persons with and without type 2 diabetes mellitus (T2DM). The prevalence rates














Table 6 Semi-maximum prevalence and interpolated age shift of selected concomitant co-morbidities 2010
Disease Men Women Total
(Year 2010) Age at semi-maximum (prevalence at
semi-maximum, R2)
Age shift (years) Age at semi-maximum (prevalence at
semi-maximum, R2)
Age shift (years) Age atsemi-maximum (prevalence at
semi-maximum, R2)
Age shift (years)
Without T2DM. With T2DM Without T2DM With T2DM Without T2DM With T2DM
Adiposity 38.0 (5.07, 0.95) 24.7 (16.97, 0.99) 13 31.8 (7.88, 0.96) <20* (24.50, 1.00) NC 34.3 (6.59, 0.96) 21.9 (20.56, 0.99) 12
Hypertension 56.5 (34.74, 0.97) 37.7 (42.39, 0.98) 19 60.8 (37.58, 0.97) 40.9 (44.21, 0.97) 20 60.5 (36.56, 0.97) 40.3 (43.54, 0.98) 20
Coronary heart disease 69.7 (16.74, 0.99) 61.5 (21.51, 0.98) 8 72.8 (12.38, 0.97) 68.9 (16.53, 1.00) 4 70.5 (13.42, 0.99) 62.5 (17.64, 0.98) 8
Stroke 71.1 (3.05, 0.97) 67.6 (4.45, 0.98) 5 74.2 (2.45, 0.94) 70.2 (3.45, 0.99) 4 72.2 (2.59, 0.97) 67.8 (3.66, 0.99) 4
Renal insufficiency 73.0 (6.97, 0.96) 66.1 (8.13, 0.97) 7 74.4 (4.54, 0.93) 66.0 (5.64, 0.98) 8 72.7 (5.12, 0.96) 64.0 (6.19, 0.99) 9
Retinopathy 70.3 (9.53, 0.98) 45.7 (15.60, 0.95) 25 69.0 (10.32, 0.96) 48.9 (16.39, 0.92) 20 69.1 (9.79, 0.97) 47.9 (16.07, 0.94) 21
The age and prevalence of concomitant co-morbidities at semi-maximum values are shown comparing insured persons with and without type 2 diabetes mellitus (T2DM) after standardization for age and sex on the
residual population of South Western Germany. R2 is the goodness of fit from the respective regression model calculating the curves. For this analysis the age groups of 20 years and older were considered only














Fig. 4 (See legend on next page.)
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of the AOK Baden-Wuerttemberg, a large statutory
health insurance including about 4 million insurants in
South Western Germany. The data show a clear increase
of the lifetime diagnosis-based prevalence of T2DM
from the year 2007 to 2010, which is still seen after ex-
cluding the demographic changes during this time
period. Notably, in older people more than 25 % suffered
from T2DM, associated with considerable comorbidity.
Given the current demographic transition, the burden of
T2DM and of diabetes associated co-morbidities will
pose an increasing challenge to the health care system.
Our data underline the need for early screening pro-
grammes as well as early treatment of co-morbidities to
encounter this dramatic development. However, several
limitations has to be considered concerning the analysis
of claims data like non-uniform or incorrect coding,
incomplete diagnosis of the physicians, lack of standard-
ized criteria of diagnosis, missing validity checks of the
diagnosis, and structural differences of the membership
of health insurances.
Lifetime diagnosis-based prevalence of T2DM
The prevalence data of our study are comparable with
recent investigations of health insured persons of the
AOK Hessen, Germany, a comparable statutory health
insurance. Those studies reported a diagnosis-based
prevalence of 9.7 % for all types of diabetes together
after standardization on the population of Germany in
2009 [14, 25]. Furthermore, the recent nationwide repre-
sentative DEGS1 survey found a slightly lower preva-
lence of known diabetes of 7.2 % in Germany in the year
2011. However in this survey the diagnosis of diabetes
was established by self-report of diabetes or self-statement
of antidiabetic drugs only, which can lead to underestima-
tion. Interestingly, a special analysis of the data of the
DEGS1 survey revealed a marked influence of the
membership to different health insurances on the preva-
lence ranging for diabetes altogether from 3.8 % up to
9.0 % with the highest value for the health insurance we
investigated in the present study [1]. Taking into account
that about 5 to 10 % of all patients with diabetes are con-
sidered to have type 1 diabetes the prevalences of our
study revealed the same magnitude as estimated in the
DEGS1 survey for the AOK health insurance data or the
analysis of the data of the AOK Hessen.
A considerably lower diagnosis-based prevalence of
T2DM was found in the recent analysis of another statu-
tory health insurance in Germany. This analysis showed
a prevalence of T2DM of only 4.7 % for Germany and
4.8 % for South Western Germany by cumulative evalu-
ation of the insured persons of the years 2008 to 2010.
However, this analysis is only partly comparable with
our results as it cumulated the data of three years. In
addition, the structure of the membership was different
to our population, which might be in correspondence
with the results of the DEGS1 survey the main reason
for the different prevalences. Furthermore, their algo-
rithm used for analysis considered the WHO-ICD-10
code E11 for the detection of persons with T2DM
only. This excluded the substantial amount of insured
persons with T2DM coded as E14 alone, which ap-
plies in our investigation about an eighth of all pa-
tients with a diabetes diagnosis [22]. In contrast, we
used an established algorithm first applied in insured
persons of the AOK Hessen with a slight modification
to focus on T2DM only [24, 25].
In addition to the prevalence of known diabetes a con-
siderable amount of undiagnosed diabetes may exist in
the population. The prevalence of undiagnosed diabetes
was estimated at 2.1 % in the DEGS1 survey for the age
group of 18 to 79 years [32]. Furthermore, the KORA
survey 2000 in Southern Germany revealed for the age
group of 55 to 74 years a prevalence of undiagnosed
diabetes of 8.2 % after screening with an oral glucose tol-
erance test. This prevalence was nearly as high as the
prevalence of known diabetes with 8.7 % [33]. This is of
particular interest due to the considerable amount of
already existing co-morbidities like polyneuropathy,
increased mortality and the increased requirement of
drugs of persons with undiagnosed diabetes [17, 34–36].
Therefore, the considerable amount of undetected dia-
betes might have led to an underestimation of the age
group related prevalence of T2DM as well as of the
prevalences of concomitant co-morbidities in our study.
The incidence rates of T2DM with 7.8 to 8.7/1000 in
our study were about twice as high as those determined
with 3.7/1000 person-years for South Western Germany
in a recent analysis of the claims data of another health
insurance. However, the prevalence of T2DM was about
half as well in that investigation, which may explain the
differences of the incidences found [22]. A higher inci-
dence rate of self-reported T2DM with 9.3/1000 person-
years was recently shown for the South of Germany by
the analysis of five regional population-based studies of
the years 1997 to 2010. However, those studies investi-
gated participants aged 45 years and over, a group with
(See figure on previous page.)
Fig. 4 Comparison of the prevalence rates of concomitant co-morbidities. The age shifts of prevalence rates in persons with and without type 2
diabetes mellitus in the AOK Baden-Wuerttemberg determined at the semi-maximum values are shown for adiposity (a) and several concomitant
co-morbidities (b-f) for the year 2010. The horizontal lines show the semi-maximum diagnosis-based prevalence and the vertical lines
the respective age belonging to the semi-maximum values. For this analysis the age groups of 20 years and older were considered only
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Table 7 Excess risk of disease for selected concomitant co-morbidities 2010
Disease Men Women Total
(Year 2010) Prevalence rates (95 % CI) Odds Ratio
(95 % CI)
Prevalence rates (95 % CI) Odds Ratio
(95 % CI)
Prevalence rates (95 % CI) Odds Ratio
(95 % CI)With T2DM Controls With T2DM Controls With T2DM Controls
Adiposity 25.98 (25.72-26.24) 10.24 (10.07-10.40) 3.08 (3.02-3.14) 31.99 (31.73-32.24) 13.64 (13.48-13.81) 2.98 (2.93-3.03) 29.31 (29.13-29.50) 12.13 (12.01-12.24) 3.00 (2.97-3.04)
Hypertension 77.40 (76.95-77.84) 57.08 (56.69-57.46) 2.58 (2.53-2.62) 81.93 (81.52-82.34) 63.14 (62.78-63.50) 2.65 (2.61-2.69) 79.91 (79.61-80.22) 60.44 (60.18-60.71) 2.60 (2.58-2.63)
Coronary heart disease 30.52 (30.24-30.80) 18.6 (18.38-18.81) 1.92 (1.89-1.96) 21.35 (21.14-21.56) 12.55 (12.39-12.71) 1.89 (1.86-1.92) 25.43 (25.26-25.60) 15.24 (15.11-15.37) 1.90 (1.87-1.92)
Stroke 5.37 (5.25-5.49) 3.23 (3.14-3.32) 1.70 (1.64-1.76) 4.16 (4.07-4.25) 2.54 (2.47-2.61) 1.67 (1.61-1.73) 4.70 (4.63-4.77) 2.85 (2.79-2.90) 1.68 (1.64-1.73)
Renal insufficiency 9.56 (9.40-9.72) 3.15 (3.06-3.24) 3.25 (3.14-3.36) 7.38 (7.25-7.5) 2.18 (2.11-2.25) 3.57 (3.45-3.70) 8.35 (8.25-8.45) 2.61 (2.56-2.67) 3.39 (3.31-3.48)
Retinopathy 25.27 (25.02-25.53) 9.14 (8.99-9.29) 3.36 (3.29-3.43) 27.38 (27.14-27.61) 13.17 (13.01-13.34) 2.48 (2.44-2.53) 26.44 (26.27-26.61) 11.38 (11.27-11.49) 2.80 (2.76-2.84)
The prevalences of concomitant co-morbidities are shown comparing all persons with type 2 diabetes mellitus (T2DM) and respective controls in a case–control-study. The controls are matched individually by age and














Fig. 5 Regional lifetime diagnosis-based prevalence. The regional variation in the diagnosis-based prevalence of type 2 diabetes mellitus is shown for
the year 2010 after standardization on the residual population of the respective distinct districts (a, c, e) or on South Western Germany (b, d, f)
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increased risk of developing a T2DM and the data are
therefore not directly comparable with our study [21].
The incidence rates found in our study are in the
same range with those in other comparable countries.
An incidence rate of 7.3/1000 person-years was deter-
mined for T2DM in England. Studies in the USA and
Canada found incidence rates of diabetes of 8/1000 in
2008 (USA) and 8.2/1000 in 2003 (Canada) respect-
ively [37–39].
Altogether, the prevalence of T2DM has risen consid-
erably in Germany over the last decades. It was about
2 % in the year 1968 in Munich and 0.7 % in 1961 ac-
cording to the former German Democratic Republic
(GDR) diabetes register with an increase up to 4.0 % in
the year 1987 [40, 41]. The German National Health
Interview and Examination Survey 1997/98 found a
prevalence of known diabetes of 4.3 % for men and
3.8 % for women in the total population of Germany
[42]. Participants of this survey took also part in the
DEGS1 survey. Comparing the results of both surveys
the DEGS1 survey confirmed an increased prevalence of
diabetes in Germany from 4.3 % to 7.2 % in about
10 years [1]. Estimates of a sample of insured persons of
the AOK Hessen have also shown an increasing
diagnosis-based prevalence of diabetes in Germany over
the years from 7.2 % in 1998 up to almost 10 % in recent
years [14, 24, 25]. In our study a significant increase of
the prevalence of T2DM over the four years was still
found after standardization of all data on the residential
population of 2007 suggesting a demographic independ-
ent factor. Beside a real increase of the occurrence of
T2DM in the last years an additional increase could par-
tially be due to a rising awareness by the medical profes-
sions as well as by the population in general.
In addition, our study provides evidence of an increase
of the prevalence of T2DM already starting at early ado-
lescence and in relatively young age groups. This is of
special interest due to a possible higher rate of complica-
tions in early-onset T2DM [43]. The increase and the
temporal course of the diagnosis-based prevalences of
T2DM are comparable to current studies in the area of
Germany and the steep increase with advancing age was
found in other investigations also [1, 24, 25]. In the re-
tirement age over a quarter of the population suffered
T2DM. In former studies indications were found for a
decrease of prevalence in the age groups over 80 or
90 years, a pattern which was not seen in our study [44].
However, we could find a decrease of the incidence of
T2DM in this age group. The constant high prevalences
with advancing age despite decreasing incidence may
point to a possible improvement of medical care of these
patients. In addition, as the occurrence of T2DM starts
to increase earlier in life, these results underline the rele-
vance of modification of established lifestyle factors in
early age already to positively influence the development
of T2DM in future [45–48].
The prevalence of diabetes in our study may consider-
ably differ from results estimated from claims data of
other health insurance companies for various reasons.
Altogether, insured persons of the AOK are known to
show a relatively high prevalence of T2DM while in-
sured persons of private health insurances show a lower
one as recently determined in the DEGS1 survey. This
observation fact is present despite standardization for
age and sex. There are disparities in the structure of the
membership of insured persons with respect to socio-
demographic and life-style factors, which might be one
explanation [1, 14, 24, 49]. These underlying differences
could partly be overcome in further investigations by the
use of pooled data from different health insurances.
Several studies have shown differences in the preva-
lence and incidence of diabetes in different regions of
Germany. A tendency towards a lower prevalence can be
found in the South of Germany [1, 22, 20, 21]. In
addition, the investigation of distinct districts in our
study showed a considerable range of the diagnosis-
based prevalence of T2DM within South Western
Germany. The differences were still evident after
standardization for age and sex. These different regional
prevalence patterns could be due to differences in the
awareness and frequency of the diagnosis of T2DM, the
non-uniform use of the WHO-ICD-10 codes by physi-
cians in different regions, or regional differences in add-
itional factors like social and economic status, regional
deprivation, intensive traffic burden or different genetic
disposition for T2DM as revealed e.g. in the DEGS1 sur-
vey or as pooled analysis of up to six population-based
studies [1, 20, 21, 50, 51]. Unfortunately, we had no suit-
able data to explore these differences further.
In the present study insurants with T2DM were deter-
mined according to the established algorithm of the ana-
lysis of the claims data of the AOK Hessen. This
algorithm had successfully been used in these studies
over years [24, 25]. In order to analyze T2DM only the
algorithm was slightly modified by excluding the code
E10, which codes type 1 diabetes. Furthermore the code
E13 was excluded as well due to the frequently use of
this code for coding of pancreoprive diabetes. This form
of diabetes is characterized by direct destruction of the
insulin producing cells due to several reasons (e.g. toxic)
and not by altered insulin-sensitivity and production.
Therefore, pancreoprive diabetes shows pathophysio-
logical similarities to type 1 diabetes. In addition, our
additional analysis of the use of the different ICD-10
codes for diabetes by the physicians revealed consider-
able multiple coding by the physicians and showed that
it is useful to consider more than one code. E.g. the code
E14 concerning undefined diabetes was used alone for
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coding without other diabetic specific codes in 13.5 %.
Most of these patients are usually regarded as T2DM
and would have been missed out in the analysis by ex-
clusion of E14 in the analysis. This may be one reason
for the lower prevalence of T2DM found in the analysis
of the claims data of another health insurance [22].
Concomitant co-morbidities
The case control analysis of the present study shows
dramatic excess risks for concomitant co-morbidities
due to vascular alterations as well as adiposity for
patients with T2DM. The respective excess risks were
between twofold and threefold on average. These differ-
ences were even more pronounced when comparing
patients with T2DM with the total population of South
Western Germany. The excess risks found are compar-
able with results of other studies [6, 8, 52, 53].
Concerning these concomitant co-morbidities it is
of further particular importance, that most of them
can be modified by therapeutic interventions. E.g. the
occurrence of concomitant co-morbidities by T2DM
is associated with increasing fasting blood glucose
and can be reduced by a good adjustment of blood
glucose levels [6, 8, 9, 54]. Furthermore, a sufficient
therapy of hypertension can markedly reduce the
mortality risk related to vascular complications of dia-
betes. A reduction of the systolic blood pressure by
10 mm Hg can reduce the mortality of ischemic heart
diseases by approximately 30 % and of strokes by 40 %
[55–57]. The increased risk of persons with adiposity to
develop a T2DM and their about three-fold increased
mortality should be an important reason for preventive
activities. Teenagers with adiposity have an up to 8-fold
increased risk to develop a T2DM [58–61]. Furthermore,
adiposity increases the risk of stroke as well as increased
blood sugar and duration of diabetes [62–64]. In addition,
approximately a third of all patients with T2DM have a
renal insufficiency 10 years after diagnosis with a high risk
to develop end-stage renal disease and diabetic retinop-
athy [65–68]. The risk of blindness is considerably in-
creased for persons with T2DM. In current examinations
it is about 2 ½-folds higher for T2DM than in the general
population [68–71]. Altogether, the occurrence of con-
comitant co-morbidities of patients with diabetes has
declined in the last decades, but the burden of disease
remained nearly unchanged due to the increased preva-
lence of diabetes [72].
In this context it is of particular interest, that the con-
comitant co-morbidities in patients with T2DM do not
only appear far more frequently but also far earlier in life
compared to persons without T2DM. These factors con-
tribute both to an increased burden of disease, and to a
reduced average life expectancy of patients with T2DM
[3, 6–8, 18, 19]. Moreover, the treatment of concomitant
co-morbidities cause on average three-quarters of all
medical costs of patients with T2DM at present [73].
Concerning the general population the determined
prevalences of concomitant co-morbidities in our ana-
lysis were tendentiously lower than in some other stud-
ies. This was especially the case for adiposity and to a
minor extent for coronary heart disease, stroke, and
chronic renal insufficiency. The lifetime prevalence in
the general population of Germany has been described
in current surveys between 20 to 23 % for adiposity, at
about 32 % for hypertension and between 7 to 9.3 % for
coronary heart disease [74–79]. These differences can be
due to the use of claims data of a health insurance com-
pany in our study whereby only physician recorded diag-
noses can be investigated missing the undiscovered ones
in the general population. In contrast, systematic screen-
ing approaches in study populations can also discover
asymptomatic disease. The use of routine claims data can
lead to a considerable underestimation especially for
diseases with an asymptomatic period, which can delay
clinical manifestation and diagnosis. In addition, the ICD-
coding of physicians for their claims can considerably
differ depending on the presented complaints of their
patients and on the extent of considering individual diag-
noses. Furthermore, the ICD-coding in administrative data
has only a limited sensitivity for identifying persons with
diabetes [80]. Finally, the social status of the insured per-
sons can influence the prevalence of morbidities in the
population as well. E.g. this was found for low social status
and increase of hypertension or diabetes [1, 79].
Strength and limitations
We analyzed the claims data of the total number of all
insured persons of the AOK Baden-Wuerttemberg, a
large statutory health insurance in South Western
Germany. Thereby about two-fifth of the total popula-
tion of South Western Germany was included. The com-
pleted claims data of the period from 2007 until 2010
were included in the analysis. The established algorithm
for claims data of the analysis of insurants of the AOK
Hessen was used for analysis with the slight modification
of using the WHO-ICD-10 codes E11, E12 and E14 only.
The relatively recent data and the large number should
ensure a good external validity of our data.
Limitations of a study based on claims data should be
considered. These are e.g. the non-uniform or incorrect
use of the WHO-ICD-10 codes by the physicians, struc-
tural differences between the membership of the particu-
lar health insurances, the completeness of recording of
diseases by the physicians, and the lack of detection of
undiagnosed T2DM. Additional restrictions are the lack
of the use of standardized criteria of diagnosis of dis-
eases and the missing comparability and validity check
of the physician’s diagnoses. All these limitations may
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have influenced the analysis and may have led to an
under- or overestimation of disease as well as to an age
shift towards later years in the present estimation.
A minor restriction of the present data analysis con-
sists in the use of the complete data set of insured per-
sons of the AOK Baden-Wuerttemberg for South
Western Germany. These data contain a small propor-
tion of persons with residence in Germany but residing
outside of the State of Baden-Wurttemberg. It was
assumed in this context that no essential alteration of
the finally calculated prevalence arose from including
these additional insured persons especially by residency
in the border zone of South Western Germany.
Conclusions
In summary our survey shows that T2DM is common in
South Western Germany and affects more than a quar-
ter of the population in the higher age groups. It is also
associated with considerable putatively treatable co-
morbidities, which are present more frequently at earlier
ages. T2DM showed major regional differences and oc-
curred more often earlier in life. Our data underline the
need for structured and timely health surveys, in view of
the diabetic epidemics early diagnosis as well as preven-
tion programmes for major diseases such as diabetes
mellitus and its concomitant treatable co-morbidities.
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